Biology subjects

Meisler, M. H.

Publications and source records attributed to Meisler, M. H..

3 recordsLinked to original sources

bioRxiv2026

CRISPR activation of PIKFYVE as potential therapy for FIG4 deficiency

Abstract/SummaryFIG4 deficiency is the cause of Charcot Marie Tooth type 4J, a neurological disorder characterized by enlarged lysosomes. Our CRISPR activation genome wide screen found that upregulation of PIKFYVE rescued the enlarged lysosome phenotype in cultured cells. To assess PIKFYVE upregulation treatment in vivo, we generated Fig4 deficient mice with CRISPR activation of Pikfyve in neurons. Pikfyve was increased 2 fold in whole brain of CRISPR activated mice. Pikfyve upregulation did not extend the 3 week survival of Fig4 deficient mice. Vacuolization of brain was not rescued. The data demonstrates that a 2 fold increase of Pikfyve is not sufficient to treat Fig4 deficiency. Further testing will be required to determine if a higher increase of Pikfyve can ameliorate the effects of FIG4 deficiency in vivo.

genetics↗

bioRxiv2025

Base Editing Rescue of Seizures and SUDEP in SCN8A Developmental Epileptic Encephalopathy

SCN8A encodes the voltage-gated sodium channel Nav1.6 which plays a key role in facilitating neuronal excitability. Mutations in SCN8A, particularly gain-of-function missense variants, are associated with SCN8A developmental and epileptic encephalopathy (DEE), a severe epilepsy syndrome characterized by spontaneous seizures, movement disorders, cognitive dysfunction, and sudden unexpected death in epilepsy (SUDEP). The recurrent SCN8A variant R1872W destabilizes inactivation of the sodium channel, resulting in neuronal hyperexcitability and onset of seizures. Current treatments, including anti-seizure medications (ASMs) that broadly target sodium channels, are often ineffective in SCN8A DEE patients and are associated with significant side effects, highlighting the need for targeted therapies. In this study, we utilized base editing as a therapeutic strategy to correct the patient derived R1872W SCN8A variant. Using two engineered mammalian cell line screens, we identified several targeting constructs that successfully reverted the R1872W variant to the reference allele. Our most effective construct, a modified adenine base editor, along with a paired successful guide RNA, was selected and packaged within a dual PhP.eB-adeno-associated virus (AAV) delivery system. This dual AAV therapy, referred to as SCN8A-ABE, was administered to mice expressing the R1872W variant at P2. Treatment with SCN8A-ABE significantly increased survival of mice expressing R1872W and either significantly reduced or completely inhibited seizure occurrence. Assessment of editing efficiencies revealed approximately 30% conversion of the mutant tryptophan to wildtype arginine observable in RNA transcripts from hippocampal and cortex tissue. Electrophysiological recordings revealed a rescue of seizure-associated neuronal hyperexcitability and a suppression of the pathogenic sodium channel behavior in treated mice. Associated comorbidities, including movement disorders and anxiety-like behaviors, were also improved in treated mice. These findings demonstrate the profound potential of base editing as a targeted and effective therapeutic approach for SCN8A DEE, addressing the underlying genetic mutation driving the disease.

bioengineering↗

bioRxiv2024

Predictive modeling provides insight into the clinical heterogeneity associated with TARS1 loss-of-function mutations

Aminoacyl-tRNA synthetases (ARSs) are ubiquitously expressed, essential enzymes that complete the first step of protein translation: ligation of amino acids to cognate tRNAs. Genes encoding ARSs have been implicated in myriad dominant and recessive phenotypes, the latter often affecting multiple tissues but with frequent involvement of the central and peripheral nervous system, liver, and lungs. Threonyl-tRNA synthetase (TARS1) encodes the enzyme that ligates threonine to tRNATHR in the cytoplasm. To date, TARS1 variants have been implicated in a recessive brittle hair phenotype. To better understand TARS1-related recessive phenotypes, we engineered three TARS1 missense mutations predicted to cause a loss-of-function effect and studied these variants in yeast and worm models. This revealed two loss-of-function mutations, including one hypomorphic allele (R433H). We next used R433H to study the effects of partial loss of TARS1 function in a compound heterozygous mouse model (R433H/null). This model presents with phenotypes reminiscent of patients with TARS1 variants and with distinct lung and skin defects. This study expands the potential clinical heterogeneity of TARS1-related recessive disease, which should guide future clinical and genetic evaluations of patient populations. SUMMARY STATEMENTThis study leverages an engineered, hypomorphic variant of threonyl-tRNA synthetase (TARS1) to capture TARS1-associated recessive phenotypes. This strategy revealed both known and previously unappreciated phenotypes, expanding the clinical heterogeneity associated with TARS1 and informing future genetic and clinical evaluations of patient populations.

genetics↗